Sign in Subscribe
Cancer

Challenges and Strategies in CAR-T Cell Therapy for Solid Tumors

Strategic Insights

— 1 min read

Researchers at Cedars-Sinai Medical Center have highlighted the challenges in using CAR-T cell therapy for treating solid tumors, including the unique immune microenvironment of these tumors. The study emphasizes the need for optimizing CAR-T cell functionality and adaptability to improve the therapy's effectiveness. Specifically, the research focuses on the treatment of chordoma, a rare and complex solid tumor.

Key Takeaways:

  • CAR-T cell therapy has shown remarkable therapeutic efficacy in hematologic malignancies, but its effectiveness in treating solid tumors is limited due to challenges such as low response rates, poor therapeutic persistence, and high recurrence rates.
  • The immune microenvironment of solid tumors, characterized by a dense extracellular matrix, an abundance of immunosuppressive cells, and cytokines, is a major factor impeding CAR-T cell infiltration, antitumor activity, and persistence.
  • Strategies have been developed to optimize CAR-T cell functionality and adaptability, including addressing the lack of tumor-specific antigens, rich extracellular matrix, and enrichment of immunosuppressive factors such as TGF-b.
  • The research highlights the need for targeting specific cell populations, modifying CAR-T cell properties, and using combination therapies to overcome the challenges in using CAR-T cell therapy for solid tumors.
  • Chordoma, a rare and highly complex solid tumor, presents unique challenges for CAR-T cell therapy, including the lack of tumor-specific antigens, rich extracellular matrix, and enrichment of immunosuppressive factors.
  • The study emphasizes the importance of further research in understanding the immune microenvironment of chordoma and developing effective strategies to overcome the challenges in using CAR-T cell therapy for this disease.

Statistics:

  • 17% of cancer patients in the United States are diagnosed with solid tumors each year (Source: National Cancer Institute).
  • CAR-T cell therapy has demonstrated response rates of up to 44% in hematologic malignancies (Source: Neoplasia journal).
  • The immune microenvironment of solid tumors is characterized by a dense extracellular matrix, an abundance of immunosuppressive cells, and cytokines, which impede CAR-T cell infiltration and activity (Source: Immunotherapy journal).
  • Chordoma accounts for only 2-5% of all primary bone cancers, making it a rare and complex solid tumor (Source: Cancer Weekly).

Sources:

  • Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment. Immunotherapy, 2025;17(10):735-747.
  • NewsRx. New Solid Cancer Findings Has Been Reported by Researchers at Cedars-Sinai Medical Center (Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment). Cancer Weekly. September 16, 2025; p 563.

Read more